Bluebird Bio Inc. (NASDAQ:BLUE)‘s stock had its “outperform” rating reiterated by equities research analysts at Cowen and Company in a research note issued on Monday.
A number of other equities analysts also recently issued reports on the company. Goldman Sachs Group Inc. upgraded Bluebird Bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 price target on the stock in a research note on Thursday, September 15th. Cantor Fitzgerald downgraded Bluebird Bio from a “hold” rating to a “sell” rating and lowered their target price for the company from $65.24 to $37.00 in a research report on Friday. Leerink Swann lifted their target price on Bluebird Bio from $67.00 to $80.00 and gave the company an “outperform” rating in a research report on Friday. Maxim Group reiterated a “buy” rating and set a $85.00 target price (down from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. Finally, Roth Capital initiated coverage on Bluebird Bio in a research report on Thursday, September 22nd. They set a “buy” rating and a $87.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and fourteen have assigned a buy rating to the company. Bluebird Bio has a consensus rating of “Buy” and an average target price of $91.60.
Shares of Bluebird Bio (NASDAQ:BLUE) traded down 2.07% during trading on Monday, reaching $55.40. The company’s stock had a trading volume of 614,082 shares. The company has a 50 day moving average of $63.71 and a 200 day moving average of $50.93. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $99.70. The company’s market cap is $2.06 billion.
Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. The firm earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The business’s quarterly revenue was down 68.6% on a year-over-year basis. During the same quarter last year, the business earned ($1.57) earnings per share. On average, analysts anticipate that Bluebird Bio will post ($6.19) EPS for the current fiscal year.
In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $67.00, for a total transaction of $27,872.00. Following the sale, the insider now directly owns 5,891 shares of the company’s stock, valued at $394,697. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.50% of the company’s stock.
A number of large investors have recently modified their holdings of BLUE. Sphera Funds Management LTD. acquired a new position in shares of Bluebird Bio during the first quarter valued at about $1,275,000. Wellington Management Group LLP acquired a new position in shares of Bluebird Bio during the first quarter valued at about $51,095,000. Tiverton Asset Management LLC acquired a new position in shares of Bluebird Bio during the first quarter valued at about $3,957,000. AXA raised its position in shares of Bluebird Bio by 19.3% in the first quarter. AXA now owns 148,851 shares of the company’s stock valued at $6,326,000 after buying an additional 24,053 shares during the period. Finally, UBS Asset Management Americas Inc. raised its position in shares of Bluebird Bio by 0.8% in the first quarter. UBS Asset Management Americas Inc. now owns 157,666 shares of the company’s stock valued at $6,701,000 after buying an additional 1,194 shares during the period.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.